Efficacy and safety of upadacitinib in the treatment of ulcerative colitis and Crohn’s disease in real clinical practice. Experience of the regional IBD Center

The aim: of this study was to evaluate the efficacy and safety of upadacitinib (UPA) in real clinical practice in patients with ulcerative colitis (UC) and Crohn’s disease (CD) in a specialized regional Center for the Diagnosis and Treatment of Inflammatory Bowel Diseases. Material and methods. A retrospective study of patients with IBD who received upadacitinib until December 31, 2024. To assess the efficacy and safety, the study included 91 patients who received treatment at the IBD Center for at least 12 weeks or until the drug was discontinued. Data were collected from October 2022 to December 31, 2024 (from 116 to 12 weeks of therapy). The following patient characteristics were analyzed: demographic parameters, number of lines of biological therapy before initiation of UPA, severity of the disease, previous treatment, presence of extraintestinal manifestations, extent of UC lesions, localization of gastrointestinal lesions and form of CD, presence of perianal CD lesions. Results. In patients with severe and moderate ulcerative colitis and Crohn’s disease resistant to standard therapy, upadacitinib demonstrated high efficacy and safety of induction and maintenance therapy in achieving clinical and endoscopic remission. Conclusion: Our clinical observation demonstrated high efficacy and safety of induction and maintenance therapy in patients with severe and moderate ulcerative colitis and Crohn’s disease resistant to standard therapy. Upadacitinib can be considered as a drug of choice in bionaive patients with moderate to severe IBD who have unfavorable prognosis factors. Our data on the high efficacy of upadacitinib in patients with failed biological therapy indicate the need to consider it as one of the preferred options in the 2nd and subsequent lines of therapy equally in patients with ulcerative colitis and Crohn’s disease.

upadacitinib, ulcerative colitis, Crohn’s disease, inflammatory bowel disease, efficacy, safety, extraintestinal manifestations

1. Maev I.V., Andreev D.N. et al. [Inflammatory bowel diseases]. Moscow. Prima Print LLC, 2023; 8-10. (in Russ.)@@ Маев И.В., Андреев Д.Н. и др. Воспалительные заболевания кишечника. M: ООО «Примапринт», 2023, 8-10.

2. Jostins L., Ripke S., Weersma R.K., Duerr R.H., McGovern D.R., Hyi K.Y. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119-124. doi: 10.1038/nature11582.

3. Long D. Crohn’s Disease and Ulcerative Colitis: From Pathophysiology to Novel Therapeutic Approaches. Biomedicines. 2024;12(3):689. doi: 10.3390/ biomedicines12030689.

4. Khavkin A.I., Naletov A.V., Fedulova E.N., Marchenko N.A. Inflammatory bowel diseases in children: diagnostic algorithms and modern therapy strategies. Questions of Dietology. 2023; 13(3): 32-42. doi: 10.20953/2224-5448-2023-3-32-42.

5. Khavkin A.I., Nalyotov A.V., Fedulova E.N., Marchenko N.A. Inflammatory bowel diseases in children: diagnostic algorithms and modern therapy strategies. Vopr. dietol. (Nutrition). 2023; 13(3): 32-42. (In Russ.) doi: 10.20953/2224-5448-2023-3-32-42.@@ Хавкин А.И., Налетов А.В., Федулова Э.Н., Марченко Н.А. Воспалительные заболевания кишечника у детей: алгоритмы диагностики и современные стратегии терапии. Вопросы диетологии. 2023; 13(3): 32-42. doi: 10.20953/2224-5448-2023-3-32-42

6. Roda G., Jharap B., Neeraj N., Colombel J.F. Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management. Clin Transl Gastroenterol. 2016;7(1): e135. doi: 10.1038/ctg.2015.63.

7. Register of medicines. (in Russ.) Available at: https://grls.rosminzdrav.ru Accessed: 05.01.2025.@@ Реестр лекарственных средств. https://grls.rosminzdrav.ru

8. Knyazev O.V., Shchukina O.B., Kagramanova A.V. et al. Experience with ustekinumab use in bionaive patients with Crohn’s disease with unfavorable prognostic factors: real clinical practice. Effective Pharmacotherapy. 2024; 20 (2): 30-40. (in Russ.) doi: 10.33978/2307-3586-2024-20-2-30-40.@@ Князев О.В., Щукина О.Б., Каграманова А.В. и др. Опыт применения устекинумаба у бионаивных пациентов с болезнью Крона, имеющих факторы неблагоприятного прогноза: реальная клиническая практика. Эффективная фармакотерапия. 2024; 20 (2): 30-40. doi: 10.33978/2307-3586-2024-20-2-30-40.

9. Waljee A.K., Wallace B.I., Cohen-Mekelburg S. et al. Development and validation of machine learning models in prediction of remission in patients with moderate to severe Crohn disease. JAMA Netw. Open. 2019; Vol. 2. doi: 10.1001/jamanetworkopen.2019.3721.

10. Gisbert J.P., Marín A.C., McNicholl A.G., Chaparro M. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment. Pharmacol.Ther. 2015;41:613-623. doi: 10.1111/apt.12616.

11. Kim J.W., Kim S.Y. The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment.Int J Mol Sci. 2021;22(21):11322. doi: 10.3390/ ijms222111322.

12. De Vries L.C.S., Wildenberg M.E., De Jonge W.J., D’Haens G.R. The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease. J Crohns Colitis. 2017; 11(7):885-893. doi: 10.1093/ecco-jcc/jjx003.

13. Olivera P., Danese S., Peyrin-Biroulet L. JAK inhibition in inflammatory bowel disease. Expert Rev ClinImmunol. 2017 Jul;13(7):693-703. doi: 10.1080/ 1744666X.2017.1291342.

14. Coskun M., Salem M., Pedersen J., Nielsen O.H. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. Pharmacol Res. 2013;76:1-8. doi: 10.1016/j.phrs.2013.06.007.

15. Mohamed M.F., Bhatnagar S., Parmentier J.M., Nakasato P., Wung P. Upadacitinib: Mechanism of action, clinical, and translational science. Clin Transl Sci. 2024 Jan;17(1): e13688. doi: 10.1111/cts.13688.

16. O’Shea J.J., Schwartz D.M., Villarino A.V., Gadina M., McInnes I.B., Laurence A. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66:311-328. doi.org/10.1146/annurev-med-051113-024537.

17. Darnell J.E. Jr., Kerr I.M., Stark G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264(5164):1415-1421. doi: 10.1126/science.8197455.

18. Sideris N., Vakirlis E., Tsentemeidou A., Kourouklidou A., Ioannides D., Sotiriou E. Under Development JAK Inhibitors for Dermatologic Diseases. Mediterr J Rheumatol. 2020;31(1):137-144. doi: 10.31138/mjr.31.1.137.

19. Russell S.M., Tayebi N., Nakajima H. et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science. 1995;270(5237):797-800. doi: 10.1126/science.270.5237.797.

20. Sandborn W.J., Feagan B.G., Loftus E.V. Jr, Peyrin-Biroulet L., Van Assche G., D’Haens G. et al. Gastroenterology. 2020;158(8):2123-2138.e8. doi: 10.1053/j.gastro.2020.01.047.15.

21. DeVries L.C.S., Wildenberg M.E., DeJonge W.J., D’Haens G.R. The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease. J Crohns Colitis. 2017;11(7):885-893. doi: 10.1093/ecco-jcc/jjx003.

22. AbbVie. Data on File: ABVRRTI71469.

23. Cohen S. et al. Safety profile of upadacitinib in Rheumatoid Arthritis: Integrated analysis from the SELECT Phase 3 Clinical Program. EULAR 2019; THU0167. doi: 10.1136/annrheumdis-2020-218510.

24. Knowles S.R., Graff L.A., Wilding H., Hewitt C., Keefer L., Mikocka-Walus A. Quality of Life in Inflammatory Bowel Disease: A Systematic Review and Meta-analyses-Part I. Inflamm Bowel Dis. 2018;24(5):966-976. doi: 10.1093/ibd/izx100.

25. Jones J.L., Nguyen G.C., Benchimol E.I. et al. The Impact of Inflammatory Bowel Disease in Canada 2018: Quality of Life. Can Assoc Gastroenterol. 2019;2 (Suppl 1): S42-S48. doi: 10.1093/jcag/gwy048.

26. Radford S.J. et al. Systematic review: the impact of inflammatory bowel disease-related fatigue on health-related quality of life. Frontline Gastroenterology. 2021;12:11-21. doi: 10.1136/flgastro-2019-101355.

27. Axel Dignass, Philip Esters, Cathrin Flauaus. Upadacitinib in Crohn’s disease. 2024: 359-370. doi: 10.1080/14656566.2024.2333964.

28. Danese S. et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399(10341):2113-2128. doi: 10.1016/S0140-6736(22)00581-5.

29. Loftus Jr E.V. et al. Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease. N Engl J Med. 2023;388(21):1966-1980. doi: 10.1056/NEJMoa2212728.

30. European Crohn’s and Colitis Organisation (ECCO) 2022 Congress: OP Abstract 33. Presented February 19, 2022,

31. Genovese M.C. et al. Efficacy and Safety of Upadacitinib in Patients With Active Psoriatic Arthritis and Inadequate Response to Biologic Disease-Modifying Anti-Rheumatic Drugs (SELECT-PsA-2): a Double-Blind, Randomized Controlled Phase 3 Trial. 2020 EULAR E-Congress; OP0223. doi: 10.1186/s13075-023-03027-5.

32. Lasa J.S. et al. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2021. doi: 10.1016/S2468-1253(21)00377-0.